NanHua Bio-medicine Co Ltd operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares NanHua Bio-medicine Co Ltd with three other
miscellaneous service companies in Asia:
NatureCell Co Ltd
of KOREA (SOUTH)
sales of 23.07 billion Korean Won [US$20.21 million]
of which 59%
was Stem Cells),
(2.07 billion Japanese Yen [US$19.71 million]
of which 100%
was Alliance), and
Sunmax Biotechnology Co Limited
based in TAIWAN
(594.15 million Taiwanese Dollars [US$20.66 million]
of which 84%
was China Mainland).
NanHua Bio-medicine Co Ltd reported sales of 133.79 million Chinese Renmimbi (US$19.98 million)
December of 2019.
increase of 41.2%
versus 2018, when the company's sales were 94.79 million Chinese Renmimbi.
This was the fourth straight year of sales growth at NanHua Bio-medicine Co Ltd.
Sales of Human Cell Detection and Storage saw an increase
that was more than double the company's growth rate: sales were up
172.8% in 2019, from
18.84 million Chinese Renmimbi to 51.40 million Chinese Renmimbi.
NanHua Bio-medicine Co Ltd also saw significant increases in sales in
Other Business (up 54.7% to 5.90 million Chinese Renmimbi)
Not all segments of NanHua Bio-medicine Co Ltd experienced an increase in sales in 2019:
sales of Other fell 17.7% to 200,630.75 Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
NanHua Bio-medicine Co Ltd also experienced decreases in sales in
Monoclonal Antibody Sales and Services (down 10.4% to 41.88 million Chinese Renmimbi)